Ganciclovir implant in the treatment of cytomegalovirus retinitis.
Publication/Presentation Date
7-1-2005
Abstract
The ganciclovir implant is a sustained-release intraocular drug delivery system used to treat cytomegalovirus retinitis that provides a high and steady-state concentration of the drug in the vitreous cavity over a period of 7-8 months. Randomized, controlled clinical trials have demonstrated a superior efficacy of the implant compared with intravenous ganciclovir. Severe adverse events associated with the implant are uncommon, though potentially blinding. In addition, the implant provides no protection against second-eye or visceral cytomegalovirus retinitis infections. This review summarizes the clinical indications for and complications associated with the ganciclovir implant.
Volume
2
Issue
4
First Page
421
Last Page
427
ISSN
1743-4440
Published In/Presented At
Chang, M., & Dunn, J. P. (2005). Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert review of medical devices, 2(4), 421–427. https://doi.org/10.1586/17434440.2.4.421
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
16293081
Department(s)
Administration and Leadership
Document Type
Article